OTTAWA, ONTARIO--(Marketwired - Aug. 29, 2014) - Following the release today of the Canada-United States Regulatory Cooperation Council (RCC) Joint Forward Plan, Russell Williams, President, Canada's Research-Based Pharmaceutical Companies (Rx&D) issued the following statement:
"Canada's Research-Based Pharmaceutical Companies (Rx&D) is pleased with the Regulatory Cooperation Council's progress to date. As noted in today's announcement, the establishment of a joint electronic submission gateway with the Food and Drug Administration (FDA) for pharmaceutical products better aligns Canada and the United States. This should lead to significant reduction of regulatory burden on submission sponsors and Canadian and U.S. regulators alike, while best using the resources of regulators and industry alike. This is an effort that our members have supported and helped implement.
Broader international alignment will help ensure that information is shared effectively and consistently, while ensuring and protecting patient safety. We look forward to more positive outcomes as Canada continues to work to align to global best practices in order to achieve both the safest and most effective regulatory regime with the least cost and complexity."
Rx&D is the association of leading research-based pharmaceutical companies dedicated to improving the health of Canadians through the discovery and development of new medicines and vaccines. Our community represents the men and women working for more than 50 member companies which invest more than $1 billion in research and development each year to fuel Canada's knowledge-based economy, contributing over $3 billion to the Canadian economy. Guided by our Code of Ethical Practices, our membership is committed to working in partnership with governments, private payers, healthcare professionals and stakeholders in a highly ethical manner.